Role of Antifungal Susceptibility Testing in Non-Aspergillus Invasive Mold Infections.

ABSTRACT: No clinical breakpoints are available to delineate antifungal drug efficacy in non-Aspergillus invasive mold infections (NAIMIs). In this analysis of 39 NAIMI episodes, the MIC of the first-line antifungal drug was the most important predictor of therapeutic response. For amphotericin B, an MIC of ≤0.5 μg/ml was significantly associated with better 6-week outcomes.

SUBMITTER: Lamoth F 

PROVIDER: S-EPMC4879309 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature